| Literature DB >> 33769293 |
Maartje Witlox1, Nadia Garnefski1, Vivian Kraaij1, Margot W M de Waal2, Filip Smit3,4,5, Ernst Bohlmeijer6, Philip Spinhoven1.
Abstract
BACKGROUND: Anxiety symptoms in older adults are prevalent and disabling but often go untreated. Most trials on psychological interventions for anxiety in later life have examined the effectiveness of face-to-face cognitive behavioral therapy (CBT). To bridge the current treatment gap, other treatment approaches and delivery formats should also be evaluated.Entities:
Keywords: acceptance and commitment therapy; anxiety; cognitive behavioral therapy; internet interventions; older adults
Mesh:
Year: 2021 PMID: 33769293 PMCID: PMC8088844 DOI: 10.2196/24366
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Instruments per measurement moment.
| Instrument | Screening | T0a | T1b (3 month) | T2 (6 month) | T3 (12 month) |
| Anxiety symptom severity (GAD-7c) | ✓d | ✓ | ✓ | ✓ | ✓ |
| Positive mental health (MHC-SFe) | —f | ✓ | ✓ | ✓ | ✓ |
| Depression symptom severity (PHQ-9g) | ✓ | ✓ | ✓ | ✓ | ✓ |
| Presence of psychiatric disordersh (MINI-Plusi) | ✓ | ✓ | ✓ | — | ✓ |
| Functional impairmenth (SDSj) | ✓ | ✓ | ✓ | — | ✓ |
| Treatment satisfaction (CSQ-8k) | — | — | ✓ | — | — |
aT0: baseline.
bT1: posttreatment.
cGAD-7: Generalized Anxiety Disorder-7.
dIndicates that the instrument was used at the specified measurement moment.
eMHC-SF: Mental Health Continuum-Short Form.
fIndicates that the instrument was not used at the specified measurement moment.
gPHQ-9: Patient Health Questionnaire-9.
hAssessed during telephone interviews by trained research assistants. Scores on these measures obtained during screening are analyzed as part of baseline.
iMINI-Plus: Mini-International Neuropsychiatric Interview-Plus.
jSDS: Sheehan Disability Scale.
kCSQ-8: Client Satisfaction Questionnaire-8.
Figure 1Flowchart of study participants. ACT: acceptance and commitment therapy; CBT: cognitive behavioral therapy.
Baseline characteristics of study sample.
| Characteristics | Blended ACTa (n=150) | CBTb (n=164) | Total sample (n=314) | |
|
| ||||
|
| Mean (SD) | 62.75 (5.69) | 63.33 (5.71) | 63.06 (5.70) |
|
| Range | 55-75 | 55-75 | 55-75 |
|
| ||||
|
| Female | 100 (66.7) | 92 (56.1) | 192 (61.2) |
|
| Male | 50 (33.3) | 72 (43.9) | 122 (38.9) |
|
| ||||
|
| Dutch | 149 (99.3) | 159 (96.9) | 308 (98.0) |
|
| Dutch and other | 0 (0.0) | 5 (3.0) | 5 (1.6) |
|
| Other | 1 (0.7) | 0 (0.0) | 1 (0.4) |
|
| ||||
|
| Low | 22 (14.7) | 15 (9.2) | 37 (11.7) |
|
| Middle | 70 (44.7) | 74 (45.1) | 144 (45.8) |
|
| High | 56 (37.3) | 74 (45.1) | 130 (41.4) |
|
| Unknown | 2 (0.6) | 1 (0.6) | 3 (0.9) |
|
| ||||
|
| Married or in a romantic relationship | 120 (80.0) | 129 (78.6) | 249 (79.3) |
|
| Not married or in a romantic relationship | 30 (20.0) | 35 (21.3) | 65 (20.7) |
|
| ||||
|
| Paid employment | 77 (51.3) | 76 (46.3) | 153 (48.7) |
|
| Voluntary work | 49 (32.6) | 56 (34.1) | 105 (33.4) |
|
| No work | 53 (35.3) | 59 (35.9) | 112 (35.6) |
|
| ||||
|
| Alone | 36 (24.0) | 39 (23.8) | 75 (23.9) |
|
| With partner | 97 (64.6) | 103 (62.8) | 200 (63.7) |
|
| With children | 11 (7.3) | 13 (7.9) | 24 (7.6) |
|
| With partner and children | 6 (4.0) | 8 (4.8) | 14 (4.5) |
|
| Other | 0 (0.0) | 1 (0.6) | 1 (0.3) |
|
| Community-dwelling | 150 (100.0) | 164 (100.0) | 314 (100.0) |
|
| ||||
|
| No somatic problems | 29 (19.3) | 32 (19.5) | 61 (19.4) |
|
| One or more somatic problems | 121 (80.7) | 132 (80.5) | 253 (80.6) |
|
|
|
|
| |
|
| SSRIc | 10 (6.7) | 12 (7.3) | 22 (7.0) |
|
| Benzodiazepine | 19 (12.7) | 15 (9.2) | 34 (10.8) |
|
| No psychotropic medication | 121 (80.7) | 137 (83.5) | 258 (82.2) |
|
| ||||
|
| Panic disorder | 10 (6.7) | 7 (4.3) | 17 (5.4) |
|
| Agoraphobia | 5 (3.3) | 5 (3.0) | 10 (3.2) |
|
| Social phobia | 5 (3.3) | 8 (4.9) | 13 (4.1) |
|
| Specific phobia | 10 (6.7) | 8 (4.8) | 18 (5.7) |
|
| OCDd | 1 (0.7) | 2 (1.2) | 3 (0.9) |
|
| PTSDe | 2 (1.3) | 1 (0.6) | 3 (0.9) |
|
| Illness anxiety disorder | 3 (2.0) | 4 (2.4) | 7 (2.2) |
|
| GADf | 17 (11.3) | 18 (10.9) | 35 (11.1) |
|
| Any anxiety disorder | 42 (28.0) | 39 (23.8) | 81 (25.8) |
|
| No anxiety disorder | 108 (72.0) | 125 (76.2) | 233 (74.2) |
aACT: acceptance and commitment therapy.
bCBT: cognitive behavioral therapy.
cSSRI: selective serotonin reuptake inhibitor.
dOCD: obsessive-compulsive disorder.
ePTSD: posttraumatic stress disorder.
fGAD: generalized anxiety disorder.
Mixed model analyses comparing the differences between the blended acceptance and commitment therapy and cognitive behavioral therapy group over time and between-group effect sizesa.
| Outcome | Unstandardized beta coefficient B | SE | Cohen | ||||||||
|
| |||||||||||
|
| T0-T1 | −3.92 | 0.26 | −15.01 (57) | <.001 | N/Ac | |||||
|
| T1-T2 | .64 | 0.28 | 2.29 (580) | .02 | N/A | |||||
|
| T1-T3 | −0.23 | 0.30 | −0.78 (20) | .45 | N/A | |||||
|
| T0-T1d condition | .18 | 0.52 | 0.35 (57) | .73 | 0.02 | |||||
|
| T1-T2d condition | −0.63 | 0.56 | −1.13 (580) | .26 | 0.15 | |||||
|
| T1-T3d condition | −0.33 | 0.60 | −0.54 (20) | .59 | 0.08 | |||||
|
| |||||||||||
|
| T0-T1 | .29 | 0.05 | 4.55 (34) | <.001 | N/A | |||||
|
| T1-T2 | .00 | 0.06 | 0.01 (173) | .99 | N/A | |||||
|
| T1-T3 | −0.06 | 0.06 | −0.90 (71) | .37 | N/A | |||||
|
| T0-T1d condition | −0.12 | 0.13 | −0.94 (34) | .36 | 0.06 | |||||
|
| T1-T2d condition | .03 | 0.12 | 0.24 (173) | .82 | 0.03 | |||||
|
| T1-T3d condition | .27 | 0.13 | 2.13 (71) | .04 | 0.29 | |||||
|
| |||||||||||
|
| T0-T1 | −3.01 | 0.26 | −11.59 (30) | <.001 | N/A | |||||
|
| T1-T2 | −0.65 | 0.27 | −2.37 (66) | .02 | N/A | |||||
|
| T1-T3 | −0.69 | 0.33 | −2.12 (42) | .04 | N/A | |||||
|
| T0-T1d condition | .31 | 0.52 | 0.59 (30) | .56 | 0.03 | |||||
|
| T1-T2d condition | −0.67 | 0.55 | −1.21 (66) | .23 | 0.16 | |||||
|
| T1-T3d condition | −0.53 | 0.66 | −0.80 (42) | .43 | 0.12 | |||||
|
|
| ||||||||||
|
| T0-T1 | −1.87 | 0.27 | −6.96 (37) | <.001 | N/A | |||||
|
| T1-T3 | −.18 | 0.31 | −0.58 (45) | .57 | N/A | |||||
|
| T0-T1d condition | .28 | 0.54 | 0.53 (37) | .60 | 0.10 | |||||
|
| T1-T3d condition | .64 | 0.62 | 1.03 (45) | .31 | 0.23 | |||||
|
| |||||||||||
|
| T0-T1 | −1.78 | 0.26 | −6.96 (37) | <.001 | N/A | |||||
|
| T1-T3 | −.15 | 0.27 | −0.55 (27) | .59 | N/A | |||||
|
| T0-T1d condition | −.18 | 0.51 | −0.35 (37) | .73 | 0.07 | |||||
|
| T1-T3d condition | 0.08 | 0.55 | 0.15 (27) | .88 | 0.03 | |||||
|
| |||||||||||
|
| T0-T1 | −1.93 | 0.22 | −8.78 (44) | <.001 | N/A | |||||
|
| T1-T3 | −.17 | 0.26 | −0.66 (73) | .51 | N/A | |||||
|
| T0-T1d condition | .02 | 0.44 | 0.05 (44) | .96 | 0.00 | |||||
|
| T1-T3d condition | −.38 | 0.51 | −0.74 (73) | .46 | 0.11 | |||||
|
| |||||||||||
|
| T1 Intercept | 22.83 | 0.35 | 65.20 (34) | <.001 | N/A | |||||
|
| T1 Condition | 3.19 | 0.70 | 4.58 (37) | <.001 | 0.78 | |||||
|
| |||||||||||
|
| T1 Intercept | −3.47 | 0.96 | −3.60j | <.001 | N/A | |||||
|
| T1 Condition | 1.28 | 0.78 | 1.64j | .10 | 3.59 | |||||
|
| T3 Intercept | −2.38 | 0.47 | −5.09j | <.001 | N/A | |||||
|
| T3 condition | .05 | 0.70 | 0.07j | .941 | 1.05 | |||||
|
| |||||||||||
|
| T1 intercept | −1.34 | 0.46 | −2.93j | .003 | N/A | |||||
|
| T1 condition | .38 | 0.62 | 0.61j | .54 | 1.46 | |||||
|
| T3 intercept | −1.39 | 0.79 | −1.75j | .08 | N/A | |||||
|
| T3 condition | −1.01 | 1.08 | −0.94j | .35 | 2.75 | |||||
aFor the MINI-Plus and CSQ-8, the condition variable was dummy coded (CBT=0, ACT=1). B is the unstandardized coefficient. T0 stands for baseline; T1 for posttreatment; T2 and T3 for 6- and 12-month follow-up, respectively.
bGAD-7: Generalized Anxiety Disorder-7.
cN/A: not applicable.
dThe presented b-coefficients of logistic mixed model regressions are log-its and effect sizes odds ratios.
eMHC-SF: Mental Health Continuum-Short Form.
fPHQ-9: Patient Health Questionnaire-9.
gSDS: Sheehan Disability Scale.
hCSQ-8: Client Satisfaction Questionnaire-8.
iMINI-Plus: Mini International Neuropsychiatric Interview-Plus.
jReported values are z-values.
Mixed model estimated means for the outcomes in both groups and within-group effect sizes.
| Outcome | T0 baseline (95% CI) | T1 posttreatment (95% CI) | T2 6-month follow-up (95% CI) | T3 12-month follow-up (95% CI) | ESa T0-T1 | ES T1-T2 | ES T1-T3 | ||||||||
|
| |||||||||||||||
|
| Blended ACTc | 8.18 (7.49-8.88) | 4.35 (3.59-5.12) | 4.67 (3.86-5.49) | 3.96 (3.09-4.83) | 0.96 | 0.10 | 0.11 | |||||||
|
| CBTd | 8.78 (8.12-9.44) | 4.76 (4.06-5.47) | 5.72 (4.99-6.45) | 4.70 (3.89-5.50) | 1.09 | 0.28 | 0.02 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 2.73 (2.54-2.91) | 2.96 (2.75-3.17) | 2.98 (2.76-3.19) | 3.04 (2.82-3.26) | 0.24 | 0.02 | 0.09 | |||||||
|
| CBT | 2.57 (2.40-2.74) | 2.92 (2.73-3.12) | 2.91 (2.72-3.10) | 2.73 (2.52-2.94) | 0.38 | 0.01 | 0.20 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 6.99 (6.28-7.71) | 4.14 (3.30-5.00) | 3.16 (2.35-3.97) | 3.19 (2.3-4.06) | 0.70 | 0.26 | 0.27 | |||||||
|
| CBT | 7.92 (7.24-8.60) | 4.76 (3.97-5.55) | 4.44 (3.71-5.18) | 4.33 (3.52-5.14) | 0.75 | 0.08 | 0.12 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 3.52 (2.94-4.11) | 1.80 (1.16-2.44) | N/Ah | 1.94 (1.17-2.71) | 0.67 | N/A | 0.06 | |||||||
|
| CBT | 3.76 (3.17-4.35) | 1.75 (1.17-2.34) | N/A | 1.25 (0.45-2.05) | 0.82 | N/A | 0.24 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 4.02 (3.51-4.53) | 2.16 (1.57-2.74) | N/A | 2.05 (1.38-2.72) | 0.75 | N/A | 0.04 | |||||||
|
| CBT | 4.08 (3.59-4.56) | 2.39 (1.86-2.91) | N/A | 2.20 (1.53-2.86) | 0.63 | N/A | 0.07 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 3.82 (3.30-4.33) | 1.90 (1.34-2.45) | N/A | 1.54 (0.84-2.23) | 0.76 | N/A | 0.16 | |||||||
|
| CBT | 3.79 (3.30-4.28) | 1.85 (1.35-2.35) | N/A | 1.87 (1.19-2.55) | 0.71 | N/A | 0.00 | |||||||
|
| |||||||||||||||
|
| Blended ACT | 0 | 0.10 (0.02-0.30) | N/A | 0.09 (0.03-0.21) | N/A | N/A | N/A | |||||||
|
| CBT | 0 | 0.02 (0.00-0.17) | N/A | 0.08 (0.03-0.19) | N/A | N/A | N/A | |||||||
|
| |||||||||||||||
|
| Blended ACT | 1 | 0.28 (0.14-0.46) | N/A | 0.08 (0.02-0.28) | N/A | N/A | N/A | |||||||
|
| CBT | 1 | 0.21 (0.10-0.39) | N/A | 0.20 (0.05-0.54) | N/A | N/A | N/A | |||||||
aES: effect size.
bGAD-7: Generalized Anxiety Disorder-7.
cACT: acceptance and commitment therapy.
dCBT: cognitive behavioral therapy.
eMHC-SF: Mental Health Continuum-Short Form.
fPHQ-9: Patient Health Questionnaire-9.
gSDS: Sheehan Disability Scale.
hN/A: not applicable.
iMINI: Mini-International Neuropsychiatric Interview.
jProbabilities of having an anxiety disorder for participants without anxiety disorder at baseline (n=233).
kProbabilities of having an anxiety disorder for participants with anxiety disorder at baseline (n=81).
Figure 2Mean Generalized Anxiety Disorder-7 (GAD-7) scores at all assessments for both conditions. ACT: acceptance and commitment therapy; CBT: cognitive behavioral therapy; GAD-7: Generalized Anxiety Disorder-7.